Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
Volume
5.94 M
Value Traded
5.20 M
Short % Float
16.36%
Days to Cover
1.0
-24.44%Week
-73.9%1 Month
-50.07%3 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
3.36 M
EPS (TTM)
-9.60
P/E Ratio
-
Ent. Value
44.77 M
Total Shares
4.52 M
Float Shares
2.27 M
Insiders
49.63%
Institutions
2.02%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
MEDS Catalyst Timeline
Dated clinical, regulatory and corporate events for DataMeds AI, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for DataMeds AI, Inc.
29Total events
3Upcoming
8Tier-1 (high impact)
2026 to 2026Coverage
Upcoming catalysts 2
TBD
T2Timing Guidance
Subscribe to view catalyst details
TBD
T2Timing Guidance
Subscribe to view catalyst details
Event history 18
▲Partnership / LicenseCorporate
DataMEDS enters amended and restated non-binding LOI with Datavault AI, DHP/REBOOT, EOS, Scilex and HealthBridge Advisors
▲Partnership / LicenseCorporate
DataMEDS licenses U.S. DTC rights to REBOOT Health AI's GLP-1 care management platform
▲Reimbursement / PricingChemoFxPost-Market
Humana Medicaid coverage policy includes ChemoFx Assay for gynecologic cancers
gynecologic cancerssource ↗
▲Reimbursement / PricingChemoFxPost-Market
ChemoFx included in Humana Medicaid coverage policy for gynecologic cancers
gynecologic cancerssource ↗
▼Restructuring LayoffsCorporate
Cost control measures implemented, primarily reductions in corporate management positions
●Oral PresentationPresentation
DataMEDS Interim Co-CEO to present 'What Patients Really Want' at 2026 National Telehealth and Virtual Care Summit
●R&D DayPresentation
DataMEDS AI Interim Co-CEO to present 'What Patients Really Want' at 2026 National Telehealth and Virtual Care Summit
▲Legal / SettlementCorporate
Settlement of Wellgistics litigation extinguishing ~$19M in liabilities and retiring 364,099 common shares
▲Partnership / LicenseCorporate
DataMeds AI and Tollo Health partner with NFL Alumni Association for Health Lives Here campaign
▲Product LaunchPost-Market
Health Lives Here media campaign rollout to general population expected to begin in North Carolina
▲Quarterly UpdateCorporate
Corexa Pharmacy preliminary September 2026 revenue surpasses $1 million, up over 66% from July 2026
●Timing GuidancePresentation
Additional details on Health Lives Here mobile app, certified pharmacies and campaign rollout staging to be provided
Past FDA Catalysts and PDUFA Decisions
How MEDS actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every MEDS program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Patel PrashantDirector, Officer (Chief Executive Officer) | Grant/Award | 5,000,000 5,000,000 held | $0.01 | 03/31/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in MEDS
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in MEDS for Q2 2026. | ||||
Ownership Trends
MEDS Short Interest
Shares sold short, counted twice a month.
16.36%
Short % of Float
of tradable shares sold short
371.4K
Shares Sold Short
-22.0% vs prior count
1.0 Low
Days to Cover
trading days of normal volume to buy every short share back
713.4K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How MEDS ranks across every disease it competes in
Competitive Position is a premium feature
See how MEDS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialMEDS News
-MEDS
Nov 13, 2026▼ -14.5%today
DataMEDS AI Reports 50% Sequential Revenue Growth in Third Quarter 2026 From Second Quarter 2026, Delivers Net Profit Per Share of $2.72 and Provides Business Update
DataMEDS AI reported a 50% increase in revenue for Q3 2026, reaching $2.7 million. The company achieved a net profit per share of $2.72, a significant turnaround from previous losses. Key drivers included the launch of the Health Lives Here app and the acquisition of Helomics, which expands their service offerings. DataMEDS also regained compliance with Nasdaq listing standards.
Read more →-MEDS
Nov 5, 2026DataMEDS AI Announces Termination of Second Amended and Restated Letter of Intent
DataMEDS AI has terminated its Second Amended and Restated letter of intent with Datavault AI and others due to unfavorable market conditions. As a result, the company will not issue shares related to this agreement. However, its existing licenses with REBOOT and Datavault AI remain intact.
Read more →-MEDS
Oct 23, 2026DataMEDS AI Establishes "Health Lives Here" Community Respiratory Program for Corexa Health Pharmacy Network
DataMEDS AI has launched the "Health Lives Here" Community Respiratory Program to enhance respiratory care through independent pharmacies. The initiative aims to improve access to vaccines and therapeutics as the cold and flu season approaches. Corexa Pharmacy in Lakeland, Florida will be the first to implement the program, which is expected to drive community health engagement.
Read more →-MEDS
Oct 22, 2026▼ -15.4%on this newsshared move
DataMEDS AI Enters Into Amended and Restated LOI to License and Acquire IP that Enables Goal-Driven Prescription Drug Telehealth, Medical Drones and Healthcare Blockchain Technologies
DataMEDS AI has entered into an amended LOI to acquire intellectual property from several partners, including Datavault AI. This move aims to enhance their Health Lives Here mobile application and support telehealth innovations. The transaction is projected to close in the fourth quarter of 2026, pending due diligence and regulatory approvals.
Read more →-MEDS
Oct 20, 2026DataMeds Regains Compliance With NASDAQ Listing Standards
DataMeds AI, Inc. announced it has regained compliance with Nasdaq Listing Rule 5550(b)(1) as of October 19, 2026. The company confirmed its stockholders' equity exceeded $2.5 million, following a notice of delisting received in April 2026. This compliance allows DataMeds to continue trading on the Nasdaq exchange.
Read more →-MEDS
Oct 16, 2026▼ -7.7%on this newsshared move
DataMeds Applauds FDA's Proposed Interim Access Policy for Compounding Using Certain Peptides and Provides Corexa Health's Peptides Roadmap
DataMeds AI praised the FDA's proposed policy for compounding certain peptides, following recommendations from the Pharmacy Compounding Advisory Committee. Corexa Health plans to leverage this regulatory change to fill prescriptions and meet rising demand. The compounded peptide market is projected to grow significantly, presenting new opportunities for the company.
Read more →-MEDS
Oct 14, 2026▼ -5.9%on this news
DataMEDS Si Licenses U.S. Rights To Reboot Health AI's Direct-To-Consumer GLP-1 Weight Management Platform
DataMeds AI has secured an exclusive license for REBOOT Health AI's GLP Management Platform, which will be integrated into its Health Lives Here app. This partnership aims to enhance patient management for those on GLP-1 medications through a subscription model. The collaboration is expected to drive revenue while providing a comprehensive approach to weight management. However, ongoing litigation regarding intellectual property may present challenges.
Read more →-MEDS
Oct 13, 2026DataMEDS SI Provides Business Update On CLIA Lab Helomics And Its Super Intelligence Predictive Oncology Division
DataMeds AI, Inc. has implemented cost control measures and refocused its workforce on commercializing the ChemoFx diagnostic test for gynecologic cancers. The company recently acquired Helomics Corporation, enhancing its predictive oncology capabilities. ChemoFx is now included in Humana's Medicaid coverage, and DataMEDS plans to relaunch its marketing efforts for the test.
Read more →-MEDS
Oct 12, 2026DataMEDS SI Announces Helomics Receives Medicaid Coverage Policy For Chemofx(R) Assay In Gynecologic Cancers
DataMeds AI's subsidiary, Helomics Corporation, has secured Medicaid coverage for its ChemoFx Assay in gynecologic cancers, as announced by Humana. This assay helps oncologists determine how a patient's tumor responds to chemotherapy, potentially improving treatment outcomes. The coverage is expected to enhance the assay's adoption and support further research into its applications.
Read more →-MEDS
Oct 1, 2026▲ +28.1%on this news
DataMeds AI's Corexa Pharmacy Surpasses $1 Million In Monthly Revenue
DataMeds AI's Corexa Pharmacy reported over $1 million in revenue for September 2026, marking a significant 66% increase from July. The growth is attributed to the expansion of its retail customer base and the launch of Tollo Health's dietary supplements. The company aims to enhance patient experiences with GLP-1 receptor agonist drugs and Long COVID support, while also upgrading its pharmacy locations.
Read more →-MEDS
Sep 28, 2026▲ +22.5%on this newsshared move
DataMeds AI and Tollo Health Announce Launch of 'Health Lives Here' Mobile Application
DataMeds AI and Tollo Health have launched the Health Lives Here mobile application, aimed at supporting users of GLP-1 receptor agonist medications. The app will initially target underserved communities and plans to expand its focus to include patients with Long COVID and cancer by late 2026. The initiative is supported by a partnership with NFL Alumni Health to enhance healthcare accessibility.
Read more →-MEDS
Sep 25, 2026▼ -11.1%on this newsshared move
DataMEDS AI To Present At 2026 National Telehealth and Virtual Care Summit
DataMeds AI's Interim Co-CEO, Gerald Commissiong, will present at the National Telehealth and Virtual Care Summit on September 28, 2026. He will discuss the increasing patient demand for ownership of health data and the company's initiatives to enhance telehealth access. The summit aims to unite healthcare leaders to explore advancements in digital health.
Read more →-MEDS
Sep 18, 2026▼ -19%on this news
DataMeds AI Litigation Settlement Extinguishes ~$19 million In Liabilities and Retires 364,099 Common Sharessked
DataMeds AI, Inc. has settled litigation concerning approximately $19 million in liabilities related to a Membership Purchase Interest Agreement. As part of the settlement, the company retired 364,099 common shares and paid $450,000 in cash. This resolution allows DataMeds to concentrate on enhancing healthcare delivery through its technology platforms.
Read more →-MEDS
Sep 15, 2026▲ +83.2%on this news· ran to +586% by day 1
DataMEDS, AI. Acquires Helomics AI Cancer Diagnostics Lab and Precision Oncology CRO Businesses from Axe Compute
DataMEDS AI, Inc. has acquired Helomics Corporation from Axe Compute for $1.5 million. This acquisition allows DataMEDS to expand its services into cancer management and improve patient outcomes, particularly in rural areas. Helomics, known for its AI-driven cancer diagnostics, will enhance DataMEDS' offerings in oncology. The deal includes no third-party debt and aims to integrate Helomics into DataMEDS' healthcare ecosystem.
Read more →-MEDS
Sep 8, 2026Datameds, AI., and Tollo Health Partner with the NFL Alumni Association for Health Lives Here National Campaign Rollout
DataMeds AI, Inc. has partnered with Tollo Health and the NFL Alumni Association to launch the Health Lives Here campaign. This initiative aims to provide underserved communities with better access to telehealth and pharmacy services through a new mobile app. The campaign will begin its rollout in North Carolina in September 2026, focusing on improving health awareness and patient data management.
Read more →-MEDS
Aug 18, 2026DataMeds AI Reports Second Quarter 2026 Financials and Provides Business Update
DataMeds AI, Inc. reported a 14% revenue increase to $1.779 million for Q2 2026, surpassing projections. The company plans to launch the Health Lives Here app in September 2026, targeting patients in rural areas. However, it also reported a significant net operating loss of $18.363 million, up from $6.672 million in the same quarter last year.
Read more →About DataMeds AI, Inc.
Headquarters3000 BAYPORT DRIVE SUITE 950, TAMPA, FL, 33607
BIOPHARMAWATCH ELITE
Trade the next MEDS catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime